Skip to main content
. 2020 Apr 23;11:1961. doi: 10.1038/s41467-020-15846-0

Fig. 8. Combination of LGR5 lineage ablation with 5-FU results in enhanced anticancer efficacy.

Fig. 8

a Outline of the experimental strategy to assess the combinatory effect of LGR5 lineage ablation with 5-FU. Following tumor organoid allografting, 5-FU was administered for the first half of the experiment (every other day, for in total 6 days). DT was administered for the second half of the experiment (every other day, for in total 6 days). b Representative growth curves showing tumor volumes in the vehicle control group (CTR), the 5-FU monotherapy group, the DT administration-only group, and the hybrid 5-FU/DT group. Black arrow: onset of DT administration. c Tumor masses from these four groups (control vs. 5-FU vs. DT vs. 5-FU-DT: 0.33 ± 0.076 g, n = 12 vs. 0.25 ± 0.066 g, n = 8 vs. 0.29 ± 0.052 g, n = 8 vs. 0.13 ± 0.020 g, n = 8). d Representative images showing tumors from these four groups. e Outlines of the experimental strategy for assessing the effects of combined LGR5 lineage ablation and 5-FU treatment. 5-FU, DT, or the combination were administered since organoid engraftment every other day, for in total 12 days. f Representative growth curves showing tumor volumes of the four groups. Black arrow: onset of administration (two-way ANOVA). g The tumor masses of these four groups (control vs. 5-FU vs. DT vs. 5-FU + DT: 0.24 ± 0.056, n = 11 vs. 0.21 ± 0.048 g, n = 8 vs. 0.16 ± 0.027 g, n = 11 vs. 0.069 ± 0.007 g, n = 8). h Representative images showing the tumors from the different groups. Mean ± SEM. Source data are provided as a Source Data file.